Loading...
•
Sep 30, 2022
Oncology Institute Q3 2022 Earnings Report
The Oncology Institute's value-based care model and growth strategy were highlighted.
Key Takeaways
The Oncology Institute's investor presentation highlighted their position as a leading value-based oncology care platform, emphasizing their disruptive model, growth opportunities, and financial overview, including a revenue guidance of $245 to $250 million for 2022.
The Oncology Institute (TOI) is disrupting oncology care with a unique value-based model.
TOI's technology platform standardizes and aligns care delivery at scale.
The company has demonstrated new market exportability and has predictable, repeatable, and scalable growth.
Tremendous near-term and long-term growth opportunities exist for TOI.
Revenue by Segment
Forward Guidance
The Oncology Institute projects continued growth and profitability, driven by value-based care contracts, expansion into new markets, and strategic acquisitions.
Positive Outlook
- New markets launch with FFS + Gainshare
- Acquisition CAGR (Top-line): 18%
- Acquisition EBITDA accretive: Year 1
- DeNovo CAGR (Top-line): 53%
- Conversion to Capitated Contracts by year 4: enabling Gross Margins >25%
Challenges Ahead
- Adjusted EBITDA and Net Income Protability projected in 2024
- Acquisitions
- De Novo Growth
- Operating Losses
- Working Capital (predominantly funding A/R)
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...